01 10Tasigna
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,958
2019 Revenue in Millions : 1,880
Growth (%) : 4
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,060
2020 Revenue in Millions : 1,958
Growth (%) : 5
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 1,923
2021 Revenue in Millions : 2,060
Growth (%) : -7
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,848
2022 Revenue in Millions : 1,923
Growth (%) : -4
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 20.80%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 1,529
2014 Revenue in Millions : 1,632
Growth (%) : 7%
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 1,739
2015 Revenue in Millions : 1,632
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 1,841
2016 Revenue in Millions : 1,739
Growth (%) : 6
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 1,874
2017 Revenue in Millions : 1,841
Growth (%) : 2%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 1,880
2018 Revenue in Millions : 1,874
Growth (%) : 0
LOOKING FOR A SUPPLIER?